Tag: Head and Neck Cancer

Oncotarget News

Oncotarget

Improved Efficacy of Pembrolizumab When Combined With sEphB4-HSA in HPV-negative EphrinB2-positive HNSCC

July 22, 2024

Future development for sEphB4-HSA in HNSCC is likely to focus on patients with HPV-negative disease where there is greatest need to improve on the outcomes with pembrolizumab monotherapy.”BUFFALO, NY-... read more

Figure 4: Everolimus reduces microvessel density (MVD) and lymphatic vessel density (LVD) in TP53 mutant HNSCC xenografts.

Oncotarget

Oncotarget | Everolimus Inhibits Angiogenesis and Lymphangiogenesis in TP53 Mutant HNSCC by Downregulating STAT3/HIF-1α/VEGF Pathway

February 9, 2023

we sought to investigate the mechanism for everolimus-induced inhibition of TP53 HNSCC.” BUFFALO, NY- February 9, 2023 – A new research paper was published in Oncotarget's Volume 14 on February... read more

Oncotarget

Oncotarget | Nectin-4 Widely Expressed in Head and Neck Squamous Cell Carcinoma

November 3, 2022

In this study, we aimed to determine the rate of Nectin-4 positivity in a contemporary cohort of HNSCC and to correlate these findings with clinico-pathological parameters.”BUFFALO, NY- November 3,... read more

Figure 1: Development of an NF-κB activity related RNA expression classifier.

Oncotarget

Oncotarget | NF-κB Over-Activation Portends Improved Outcomes in HPV+ HNSCC

May 25, 2022

Since clinicians are exploring therapeutic deintensification for HPV+ HNSCC, identifying patients with good or poor prognosis using the NF-κB Activity Classifier may be useful to guide therapeutic decisions.”BUFFALO,... read more

Dr. Brian Van Tine and Dr. Charles Schutt from Washington University in St. Louis

Oncotarget

Behind the Study: Genomic, Neoantigen Evolution in Head, Neck Cancer

January 10, 2022

Dr. Brian Van Tine and Dr. Charles Schutt from Washington University in St. Louis discuss their 2021 research published by Oncotarget, entitled, “Genomic and neoantigen evolution from... read more